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Abstract : IgA nephropathy （IgAN） is characterized by mesangial deposition of 
IgA, C3, and often IgM.  We examined the relationship among IgM deposition, 
clinical features, and renal outcome in IgAN patients who underwent combined 
treatment of tonsillectomy with steroid pulse therapy （Tx-SP）.  We retrospectively 
reviewed 73 IgAN patients treated with Tx-SP from March 2006 to March 2014.  
The patients were divided into those with moderate （2＋） to severe （3＋） mesan-
gial IgM deposition （Prominent IgM-positive patients, P-Group） and those with 
negative （-） to faint （1＋） deposition （the “Other” patients, O-Group）.  Using 
propensity scores to minimize confounding factors, 11 propensity score-matched 
patients with O-Group （mO-Group） were compared to 11 P-Group patients.  The 
study out come was dened as urinary protein grade by urine test strip before Tx-
SP and one year after Tx-SP.  P-Group patients exhibited an increased severity 
of protein uria compared to O-Group （p＝0.018） and mO-Group patients （p＝
0.009） before Tx-SP.  After Tx-SP, proteinuria was signicantly ameliorated in the 
P-Group, reach ing the same severity recorded in the O-Group （p＝0.007） and 
mO-Group （p＝0.021）.  No signicant differences were noted between P-Group 
and mO-Group in microhematuria, serum creatinine level, and histological severity.  
Prominent IgM deposition is associated with severe proteinuria in IgAN.  However, 
Tx-SP induces a sufcient reduction in the severity of proteinuria in IgM-positive 
IgAN.
Key words : IgA nephropathy, IgM deposition, proteinuria, tonsillectomy, steroid 
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Introduction
　IgA nephropathy （IgAN） is the most common lesion causing primary glomerulonephritis in 
developed countries, and its only clinical manifestation is hematuria or proteinuria 1-8）.  IgAN 
diagnosis can only be conrmed by kidney biopsy, where pathognomonic ndings on immuno-
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uorescence microscopy typically show prominent glomerular deposits of IgA （often accompanied 
by C3 and IgG） in the mesangium and along the glomerular capillary wall.  Proteinuria is a 
serious risk factor of disease progression in IgAN patients 9）.  While two general approaches have 
been developed to slow such progression – namely blood pressure control using angiotensin-con-
verting enzyme inhibitors or angiotensin II receptor blockers and therapy with glucocorticoids 10） 
– combined treatment of tonsillectomy with steroid pulse therapy （Tx-SP） has been reported to 
induce clinical remission of IgAN, representing a more promising, proactive therapy 11）.
　Despite progress, the indications for Tx-SP remain unclear.  Differences in disease severity and 
the presence of multiple subtypes of IgAN have been observed, with some reports of patients 
with IgM-positive IgAN having more severe proteinuria than those with IgM-negative IgAN. 
Further study to corroborate these claims is necessary 12，13）.
　Here, we compared the clinical features of Prominent IgM-positive （≥ 2＋  intensity） IgAN 
patients with other IgAN patients and evaluated the clinical response to Tx-SP treatment in both 
groups.
Methods
Study design and patients
　Our retrospective cohort study was conducted from March 2006 to March 2014, and approved 
by the Showa University Fujigaoka Hospital Institutional Review Board.
　A total of 119 patients aged 16 years or older were diagnosed with IgAN at Showa Uni-
versity Fujigaoka Hospital, and received a combined treatment of tonsillectomy with steroid 
pulse therapy （Tx-SP）.  IgAN was diagnosed based on light microscopy ndings of mesangial 
proliferative changes, immunouorescence （IF） ndings of mesangial IgA and C3 deposition, and 
electron microscopy ndings of electron-dense deposits in glomerular mesangial tissue obtained 
by renal biopsy.  Of the initial 119 patients, 46 were excluded from the study due to more than 
a year lapsing between renal biopsy and Tx-SP or for having a history of systemic disease, such 
as diabetes mellitus, systemic lupus erythematosus, severe infection, or secondary IgAN.  Clini-
cal parameters of the 73 patients without missing data are shown in Table 1 and include age, 
sex, medication history, qualitative urinary protein （UP） level, urinary red blood cell （U-RBC） 
count, serum creatinine （sCr） levels, and estimated glomerular ltration rate ［eGFR ; calculated 
using the Modication of Diet in Renal Disease formula for Japanese.  eGFR＝186.3×sCr-1.154×
Age-0.203 （×0.742 if female）×0.881）.
　Qualitative urinary protein level was converted to a score using a urine test strip as follows : 
negative / Grade 0, 1＋/ Grade 1, 2＋/ Grade 2, and ≥ 3＋/ Grade 3.  U-RBC count was also 
converted into a score based on the number of red blood cells in a high-power eld （x400） as 
follows : none-4 / Grade 0, 5-9 / Grade 1, 10-29 / Grade 2, and ≥ 30 / Grade 3.  All clinical param-
eters were measured at two points.  Baseline data were collected at the time of hospitalization 
for the purpose of renal biopsy （Before） and follow-up data were collected in the outpatient 
section at one year after the start of Tx-SP （After）.
　The Tx-SP protocol states that, for tonsillectomy, the tonsils are to be examined by an otorh-
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inolaryngologist during surgery （after obtaining informed consent）, regardless of the gross appear-
ance of the tonsils and even in the absence of episodes of recurrent tonsillitis or gross hema-
turia with tonsillitis 14）.  During the rst year after tonsillectomy, Tx-SP should be administered 
as follows : high-dose methylprednisolone （0.5 g / day 3 times a week for 3 consecutive weeks）, 
followed by oral prednisolone at an initial dose of 30 mg every other day, with gradual tapering 
of the dose over the course of 1 year.  The study outcome was dened as urinary protein grade 
by urine test strip before Tx-SP and one year after Tx-SP.
Pathological analysis
　Renal tissue samples obtained by percutaneous needle biopsy were divided into three portions, 
which were processed separately for study by light, IF, and electron microscopy, respectively, using 
standard techniques.  For light microscopy, the renal tissue samples were xed in 4 % buffered 
formaldehyde, embedded in Paraplast, and stained with hematoxylin and eosin, periodic acid-
Schiff, periodic acid methenamine silver, and Masson’s trichrome.  For IF microscopy, the renal 
tissue samples were frozen in liquid nitrogen, and cryostat sections were stained with uorescein 
isothiocyanate-labeled antisera to human IgA, IgG1, IgG4, IgM, kappa and lambda light chains, 
C3, C1q, C4, and brinogen.  The histologic severity was graded using Clinical Guides for IgA 
Nephropathy in Japan, third version 15）.  Immunouorescence staining level was converted into 
a score of immunoglobulin deposition in the mesangial matrix, as follows : Grade 0 : – ～ ± , 
Grade 1 : ＋, Grade 2 : ＋＋, Grade 3 : ＋＋＋.
Table 1.  Clinical ndings at the time of renal biopsy
Total number of patients, n 73
Age, years 35.1 ± 13.7
Sex （male / female, n） 47 / 26
medication, n （%）
  ACE Inhibitor 3 （4.1）
  Angiotensin II receptor blockers 30 （41.1）
  Dipyridamole 17 （23.3）
  Dilazep 14 （19.2）
UP, grades （0 / 1 / 2 / 3, n） 25 / 22 / 22 / 4
U-RBC, grades （0 / 1 / 2 / 3, n） 18 / 12 / 27 / 16
S-Cr, mg / dl 0.93 ± 0.26
eGFR, ml / min / 1.73 m2 75.56 ± 22.71
Values are presented as mean ± SD
ACE, angiotensin-converting enzyme ; UP, qualitative 
urinary protein （Grade 0 : trace, Grade 1 : 1＋ , Grade 2 : 
2＋ , Grade 3 : ≥ 3＋）; U-RBC, urinary red blood cell 
count in a high-power eld （Grade 0 : 0-4, Grade 1 : 5-9, 
Grade 2 : 10-29, Grade 3 : ≥ 30）; S-Cr, serum creati nine 
levels ; eGFR, estimated glomerular ltration rate
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Statistical analysis
　We used a matched cohort approach based on the presence of IgM deposition in IgAN 
patients to minimize the influence of confounding factors.  Propensity score matching is a 
method of adjusting for the observed characteristics of non-randomly assigned patients 16）.  In 
this study, we matched the number of moderate （2＋） to severe （3＋） mesangial IgM deposi-
tion patients （collectively “Prominent IgM-positive patients”） with negative （-） to faint （1＋） 
mesangial IgM deposition patients （collectively the “other” patients） after calculating a pro-
pensity score for each patient.  We derived the propensity score from a multilogistic regression 
model containing the following variables : age, sex, and medication history.  Propensity scoring 
analysis was used to adjust for selection bias.  In this way, patients were divided into three 
groups according to mesangial deposition : Prominent IgM-positive patients （P-Group : n＝11）, 
the “Other” patients （O-Group : n＝62）, and propensity score-matched patients （Prominent IgM-
positive patients with the other patients ; mO-Group : n＝11）.
　Results are expressed as either mean ±  standard deviation or as a percentage.  Non-
parametric variables were compared using the Mann-Whitney U test, while categorical variables 
were compared using Fisher’s exact test.  P-values less than 0.05 were considered statistically 
signicant.  Results were analyzed using JMP Pro 11.0.0 （SAS Institute Inc., Cary, NC, USA）.
Results
　The characteristics of the three groups are summarized and compared in Table 2.  Age, sex, 
urine RBC, sCr, and eGFR were comparable among the three groups.  However, UP grade 
was higher in the P-Group than in either the O-Group （UP Grade 0 / 1 / 2 / 3 : 0 / 5 / 6 / 0 vs. 
25 / 17 / 16 / 4, p＝0.018） or mO-Group （vs.  4 / 0 / 6 / 1, p＝0.009） before Tx-SP.  After Tx-
SP, UP grade in the P-Group decreased signicantly, reaching the same grade as in the other 
patients （slope of urinary protein Grade -3 / -2 / -1 / 0 / 1 : 0 / 3 / 8 / 0 / 0 vs.  2 / 12 / 17 / 29 in 
O-Group, p＝0.007 ; and vs.  0 / 5 / 2 / 4 / 0 in the mO-Group, p＝0.021）.
　Table 3 details the pathological features of the Prominent IgM-positive and matched patients. 
No marked histological differences were noted between the P-Group and mO-Group, including 
histological severity grade （1 / 2 / 3 / 4）: 5 / 4 / 1 / 1 vs.  5 / 4 / 1 / 1, p＝1.000.  There was also no 
signicant difference between P-Group and mO-Group in the mesangial deposition of IgG and 
C1q, a parameter that has been associated with renal dysfunction in previous studies 17，18）.
Discussion
　In the present study, we examined the effect of Tx-SP on proteinuria in IgAN patients inde-
pendent of glomerular prominent IgM deposition levels.  Prominent IgM deposition in the glom-
erulus was associated with severe proteinuria in patients with IgAN, despite a lack of marked 
differences in histological severity grade between patients with and without prominent IgM depo-
sition.  We also noted a decrease in urinary protein excretion in Prominent IgM-positive patients 
after Tx-SP to levels similar to those observed in the other patients.  Persistent proteinuria is a 
risk factor for poor prognosis in renal function 9，19）, thus we expect that Tx-SP could improve the 
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renal prognosis of Prominent IgM-positive IgAN patients.
　IgAN is understood to have multiple subtypes ; for example, deposition of IgG or IgM is 
not believed to affect renal prognosis in IgAN patients 20）, and children with IgAN found to be 
positive for IgM or C1q at biopsy can show severe proteinuria 12）.  Previous studies have widely 
dened IgM deposition as a score of ≥ 1＋ 12）.  However, herein we dened IgM deposition of 
2＋  to 3＋  as “Prominent IgM-positive”, representing the high-level deposition group.  In this 
way, we could clearly draw a link between high IgM deposition and proteinuria, as an IgM 
deposits in the mesangium region of ≥ 2＋  was listed among the definitive findings of IgM 
nephropathy （IgMN）21）.  IgMN is glomerulonephritis with proteinuria, similar to IgAN, but 
without all the diagnostic indications of IgAN, and IgMN has been associated with nephrotic 
syndromes such as minimal change disease （MCD） and focal segmental glomerulosclerosis 
（FSGS）22，23）.
　We suspect that Prominent IgM-positive IgA nephropathy patients may be at risk of develop-
ing not only size selectivity disorder due to glomerulus capillaritis, but also charge selectivity 
Table 2.  Comparison of clinical variables
Unmatched cohort p＊ Matched cohort p＊＊
P-Group
（n＝11）
O-Group
（n＝62）
mO-Group
（n＝11）
Age, years 34.8 ± 13.1 35.2 ± 13.9 0.865 35.7 ± 14.7 0.818
Sex （Male / Female） 6 / 5 41 / 21 0.506 6 / 5 1.000
UP, grades （0 / 1 / 2 / 3）
 Before 0 / 5 / 6 / 0 25 / 17 / 16 / 4 0.018 4 / 0 / 6 / 1 0.009
 After 8 / 3 / 0 / 0 48 / 12 / 2 / 0 0.777 8 / 3 / 0 / 0 1.000
 ΔUP （-3 / -2 / -1 / 0 / 1） 0 / 3 / 8 / 0 / 0 2 / 12 / 17 / 29 / 2 0.007 0 / 5 / 2 / 4 / 0 0.021
U-RBC, grades （0 / 1 / 2 / 3）
 Before 3 / 1 / 5 / 2 15 / 11 / 22 / 14 0.886 1 / 2 / 7 / 1 0.643
 After 9 / 2 / 0 / 0 52 / 4 / 5 / 1 0.458 9 / 2 / 0 / 0 1.000
 ΔU-RBC （-3 /-2 /-1 / 0 / 1 / 2） 1 / 5 / 2 / 3 / 0 / 0 10 / 19 / 15 / 16 / 1 / 1 0.917 1 / 5 / 4 / 1 / 0 / 0 0.712
sCr, mg / dl
 Before  0.87 ± 0.26  0.94 ± 0.26 0.287   0.93 ± 0.28 0.450
 After  0.83 ± 0.21  0.93 ± 0.26 0.257   0.92 ± 0.26 0.576
 Δ sCr -0.04 ± 0.12 -0.02 ± 0.18 0.589 -0.01 ± 0.17 0.768
eGFR, ml / min / 1.73 m2
 Before  79.35 ± 23.06  74.88 ± 22.77 0.469   72.20 ± 17.46 0.450
 After   81.94 ± 26.71  75.20 ± 20.94 0.611   72.33 ± 20.38 0.375
 Δ eGFR   2.59 ± 14.09   0.31 ± 17.49 0.568    0.13 ± 17.78 0.622
P-Group, IgA nephropathy patients with moderate （2＋） to severe （3＋） mesangial IgM deposition ; O-Group, 
IgA nephropathy patients with negative （-） to faint （＋） mesangial IgM deposition ; mO-Group, matched IgA 
nephropathy patients with negative （-） to faint （＋） mesangial IgM deposition ; UP, urinary protein qualitative 
（Grade 0 : trace, Grade 1 : 1＋ , Grade 2 : 2＋ , Grade 3 : ≥ 3＋） ; U-RBC, urinary red blood cell sediments /
high-power eld （Grade 0 : 0-4, Grade 1 : 5-9, Grade 2 : 10-29, Grade 3 : ≥ 30）; sCr, serum creatinine ; eGFR, 
estimated glomerular ltration rate ; ＊p-value for the 62 unmatched other patients vs. the Prominent IgM-positive 
patients ; ＊＊p-value for the 11 matched other patients vs. the Prominent IgM-positive patients.
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disorder, as recorded with nephrotic syndromes such as MCD and FSGS.  These suspicions are 
based on the fact that initial proteinuria showed the only difference in clinical parameters and 
degree of histological damage on renal biopsy between the P-Group and mO-Group in the pres-
ent study.
　Several limitations to our study warrant mention.  First, proteinuria was evaluated qualitatively, 
rather than quantitatively, due to quantitative data not being measured at all time points based 
on the physician’s decision.  Urinary protein quantitative data are generally measured at the 
time of hospitalization for the purpose of renal biopsy, but only rarely in outpatients after Tx-
SP.  Therefore we could not use the data we had in this analysis （Table 4）.  Second, we only 
assessed the presence of glomerular lesions in our histological evaluation, not framework disorder, 
as our histological evaluation referenced renal biopsy evaluation results and was conducted by 
the attending physician based on medical records, thereby preventing observer bias.  Oxford 
categorization criteria were established in 2009, and no stromal evaluation was conducted before 
that point.  We therefore used “Clinical Guides for IgA Nephropathy in Japan, third version” 15） 
to describe histological disease severity.  Third, Tx-SP was performed in this study, but steroid 
pulse therapy alone might be effective.  We believe that the severe proteinuria observed in 
Prominent IgM-positive IgAN is due to the presence of charge selectivity disorder, similar to 
that observed with nephrotic syndrome.  Because steroid therapy itself is a treatment modality of 
nephrotic syndrome, tonsillectomy may not be necessary.  Future investigations should take these 
three points into account.
Table 3.  Histological appearance at time of renal biopsy
P-Group
（n＝11）
mO-Group
（n＝11） p
H-Grade （1 / 2 / 3 / 4） 5 / 4 / 1 / 1 5 / 4 / 1 / 1 1.000
Immunouorescence staining Grade （0 / 1 / 2 / 3）
  IgG 7 / 3 / 1 / 0 8 / 3 / 0 / 0 1.000
  IgA 0 / 9 / 2 / 0 2 / 8 / 1 / 0 0.587
  IgM 0 / 0 / 11 / 0 4 / 7 / 0 / 0 ＜ 0.001
  Fbg 4 / 6 / 1 / 0 7 / 4 / 0 / 0 0.395
  C3 1 / 2 / 8 / 0 0 / 1 / 10 / 0 0.587
  C1q 9 / 2 / 0 / 0 10 / 1 / 0 / 0 1.000
  C4 9 / 2 / 0 / 0 10 / 1 / 0 / 0 1.000
  kappa 2 / 6 / 3 / 0 2 / 8 / 1 / 0 0.825
  lambda 0 / 1 / 9 / 1 1 / 4 / 6 / 0 0.220
P-Group, IgA nephropathy patients with moderate （2＋） to severe （3＋） 
mesangial IgM deposition ; mO-Group, matched IgA nephropathy patients with 
negative （-） to faint （＋） mesangial IgM deposition ; H-Grade, glomeruli with 
lesions associated with renal prognosis / total number of glomeruli （Grade 1 : 
0%-24.9%, Grade 2 : 25%-49.9%, Grade 3 : 50%-74.9%, Grade 4 : ≥ 75%）
Immunouorescence staining Grade is deposition of immunoglobu lin in mesan-
gial matrix （Grade 0 : -　～ ± , Grade 1 : ＋, Grade 2 : ＋＋, Grade 3 : ＋＋＋）
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　In conclusion, prominent IgM deposition in glomerulus is associated with severe proteinuria in 
patients with IgAN.  Our study conrms that Tx-SP induces a marked reduction of proteinuria 
severity in Prominent IgM-positive IgAN patients and may therefore represent a powerful thera-
peutic strategy in this particular patient population.
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